NASDAQ:YMAB - Nasdaq - US9842411095 - Common Stock - Currency: USD
4.41
+0.3 (+7.3%)
The current stock price of YMAB is 4.41 USD. In the past month the price decreased by -5.36%. In the past year, price decreased by -74.29%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.33 | 351.09B | ||
AMGN | AMGEN INC | 13.55 | 151.20B | ||
GILD | GILEAD SCIENCES INC | 13.4 | 129.08B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1728.1 | 128.84B | ||
REGN | REGENERON PHARMACEUTICALS | 13.67 | 65.39B | ||
ARGX | ARGENX SE - ADR | 341.93 | 39.67B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.74B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.57B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.23B | ||
NTRA | NATERA INC | N/A | 21.18B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.72B | ||
BIIB | BIOGEN INC | 7.81 | 18.10B |
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. The company is headquartered in Princeton, New Jersey and currently employs 107 full-time employees. The company went IPO on 2018-09-21. The firm is focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform (PRIT), and bispecific antibodies generated using the Y-BiClone platform. Its advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), the first food and drug administration (FDA)-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody, or monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm derived tumors and sarcomas.
Y-MABS THERAPEUTICS INC
202 Carnegie Center, Suite 301
Princeton NEW JERSEY 10169 US
CEO: Claus Juan Moller San Pedro
Employees: 104
Phone: 16468858505
The current stock price of YMAB is 4.41 USD. The price increased by 7.3% in the last trading session.
The exchange symbol of Y-MABS THERAPEUTICS INC is YMAB and it is listed on the Nasdaq exchange.
YMAB stock is listed on the Nasdaq exchange.
17 analysts have analysed YMAB and the average price target is 16.13 USD. This implies a price increase of 265.86% is expected in the next year compared to the current price of 4.41. Check the Y-MABS THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
Y-MABS THERAPEUTICS INC (YMAB) has a market capitalization of 199.68M USD. This makes YMAB a Micro Cap stock.
Y-MABS THERAPEUTICS INC (YMAB) currently has 104 employees.
Y-MABS THERAPEUTICS INC (YMAB) has a support level at 4.09 and a resistance level at 4.42. Check the full technical report for a detailed analysis of YMAB support and resistance levels.
The Revenue of Y-MABS THERAPEUTICS INC (YMAB) is expected to decline by -6.77% in the next year. Check the estimates tab for more information on the YMAB EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
YMAB does not pay a dividend.
Y-MABS THERAPEUTICS INC (YMAB) will report earnings on 2025-05-12, after the market close.
Y-MABS THERAPEUTICS INC (YMAB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.67).
The outstanding short interest for Y-MABS THERAPEUTICS INC (YMAB) is 7.77% of its float. Check the ownership tab for more information on the YMAB short interest.
ChartMill assigns a fundamental rating of 3 / 10 to YMAB. The financial health of YMAB is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months YMAB reported a non-GAAP Earnings per Share(EPS) of -0.67. The EPS decreased by -36.73% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -24.74% | ||
ROE | -32.24% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 80% to YMAB. The Buy consensus is the average rating of analysts ratings from 17 analysts.
For the next year, analysts expect an EPS growth of -49.07% and a revenue growth -6.77% for YMAB